




Argos Therapeutics  
Investor Relations Department  
4233 Technology Drive  
Durham, NC 27704  
United States

[Visit IR website](#)   
[Sign-up for Email alerts](#) 

**NASDAQ: ARGS**


Last Trade:	1.35
Trade Time:	12:13 PM ET Feb 21, 2018
Change:	-0.02  (-1.460%)
Day Range	1.33 - 1.40
52-Week Range	1.33 - 32.00
Volume	95,766

Stock information is provided by eSignal,  
stock charts provided by EDGAR Online.  
Stock data is delayed approximately 20  
minutes.

## Company Profile

Argos Therapeutics is a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases based on its Arcelis™ technology platform. Using biological components from each patient, Arcelis-based immunotherapies employ the patient's dendritic cells to activate an immune response specific to the patient's disease. Argos' most advanced product candidates include AGS-003 for the treatment of metastatic renal cell carcinoma, or mRCC, and AGS-004 for the treatment of HIV. [\(more\)](#)

## Stock Performance



## Press Releases [\[ View all \]](#)

- Feb 15, 2018*  
[Argos Announces Issuance of Patent Covering the Foundation<sup>®</sup> for Manufacturing its HIV Immunotherapy](#)
- Feb 5, 2018*  
[Argos Obtains Option to License PD1 Checkpoint Inhibitors](#)
- Jan 18, 2018*  
[Argos Announces One-for-Twenty Reverse Stock Split](#)
- Jan 8, 2018*  
[Argos Announces \\$1.5 Million Equity Investment by Lummy \(Hong Kong\), Ltd.](#)
- Nov 28, 2017*  
[Argos Provides Financial Update](#)

## Financials [\[ View all \]](#)

- Mar 16, 2017*  
[Annual Report \(10-K\)](#)
- Jul 6, 2017*  
[Proxy Statement \(DEF 14A\)](#)
- Nov 9, 2017*  
[Quarterly Report \(10-Q\)](#)
- Aug 9, 2017*  
[Quarterly Report \(10-Q\)](#)
- May 10, 2017*  
[Quarterly Report \(10-Q\)](#)